TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Pembrolizumab;   Drug: IL-12 gene therapy;   Drug: L-NMMA Sponsors:   The Methodist Hospital System;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials